心脏再同步治疗加除颤器增加器械并发症:一项欧洲多中心队列研究
该欧洲多中心观察性队列纳入3008例无持续性室性心律失常、接受CRT植入的缺血性或非缺血性扩张型心肌病患者,比较CRT-D与CRT-P的器械相关并发症。倾向评分与竞争风险分析显示,两组围术期并发症无显著差异,但CRT-D与晚期并发症风险增加独立相关,主要为器械相关感染。
要点
- CRT-D与CRT-P围术期并发症风险相似(OR=1.20,95%CI 0.72-2.00,p=0.47)。
- CRT-D与晚期并发症风险增加独立相关(HR=1.68,95%CI 1.27-2.23,p=0.001)。
- CRT-D与器械相关感染风险增加相关(HR=2.10,95%CI 1.18-3.45,p=0.004)。
核心结论
- 与CRT-P相比,CRT-D围术期并发症风险相似,但晚期并发症风险增加,主要为感染。
- 在决定植入CRT是否加用除颤器时需考虑上述并发症风险差异。
研究设计与样本
- 欧洲多中心观察性队列研究,纳入3008例无持续性室性心律失常、接受CRT植入的缺血性或非缺血性扩张型心肌病患者。
- CRT-D组1785例,CRT-P组1223例,采用倾向评分与竞争风险分析评估需外科再干预的显著器械相关并发症风险。
主要发现
- 急性并发症发生于148例(4.9%),两组无显著差异(OR=1.20,95%CI 0.72-2.00,p=0.47)。
- 平均随访41.4±29个月,晚期并发症发生于475例,CRT-D与CRT-P年发生率分别为26(95%CI 9-43)和15(95%CI 6-24)/1000患者年。
- CRT-D与晚期并发症增加独立相关(HR=1.68,95%CI 1.27-2.23,p=0.001),尤其与器械相关感染相关(HR=2.10,95%CI 1.18-3.45,p=0.004)。
- 急性并发症不预测总体晚期并发症,但预测器械相关感染(HR=2.85,95%CI 1.71-4.56,p<0.001)。
临床怎么用
- 在CRT适应证患者选择CRT-P或CRT-D时,除考虑除颤获益外,应权衡CRT-D晚期并发症(尤其感染)风险增加。
- 发生急性并发症的患者后续器械相关感染风险较高,需加强监测。
局限性
- 观察性研究设计,即使采用倾向评分仍可能存在残余混杂。
- 不适当放电仅纳入因导线故障需修正者,未全面评估除颤器相关不适当治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients indicated for cardiac resynchronisation therapy (CRT), the choice between a CRT-pacemaker (CRT-P) versus defibrillator (CRT-D) remains controversial and indications in this setting have not been well delineated. Apart from inappropriate therapies, which are inherent to the presence of a defibrillator, whether adding defibrillator to CRT in the primary prevention setting impacts risk of other acute and late device-related complications has not been well studied and may bear relevance for device selection. METHODS: Observational multicentre European cohort study of 3008 consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy and no history of sustained ventricular arrhythmias, undergoing CRT implantation with (CRT-D, n=1785) or without (CRT-P, n=1223) defibrillator. Using propensity score and competing risk analyses, we assessed the risk of significant device-related complications requiring surgical reintervention. Inappropriate shocks were not considered except those due to lead malfunction requiring lead revision. RESULTS: Acute complications occurred in 148 patients (4.9%), without significant difference between groups, even after considering potential confounders (OR=1.20, 95% CI 0.72 to 2.00, p=0.47). During a mean follow-up of 41.4±29 months, late complications occurred in 475 patients, giving an annual incidence rate of 26 (95% CI 9 to 43) and 15 (95% CI 6 to 24) per 1000 patient-years in CRT-D and CRT-P patients, respectively. CRT-D was independently associated with increased occurrence of late complications (HR=1.68, 95% CI 1.27 to 2.23, p=0.001). In particular, when compared with CRT-P, CRT-D was associated with an increased risk of device-related infection (HR 2.10, 95% CI 1.18 to 3.45, p=0.004). Acute complications did not predict overall late complications, but predicted device-related infection (HR 2.85, 95% CI 1.71 to 4.56, p<0.001). CONCLUSIONS: Compared with CRT-P, CRT-D is associated with a similar risk of periprocedural complications but increased risk of long-term complications, mainly infection. This needs to be considered in the decision of implanting CRT with or without a defibrillator.
引用
- Barra S, Providência R, Boveda S, et al. Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart. 2018. PMID: 29540431. doi:10.1136/heartjnl-2017-312546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。